UTMD 📈 Utah Medical Products - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9174881089

UTMD: Medical Devices, Fetal Monitoring, Catheters, Electrodes, Surgical Tools

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah. Web URL: https://www.utahmed.com

Additional Sources for UTMD Stock

UTMD Stock Overview

Market Cap in USD 216m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Supplies
IPO / Inception 1999-03-08

UTMD Stock Ratings

Growth 5y -51.9%
Fundamental 49.9%
Dividend 39.3%
Rel. Strength Industry -1146
Analysts -
Fair Price Momentum 53.66 USD
Fair Price DCF 130.71 USD

UTMD Dividends

Dividend Yield 12m 1.47%
Yield on Cost 5y 0.91%
Annual Growth 5y 1.41%
Payout Consistency 62.3%

UTMD Growth Ratios

Growth Correlation 3m -59.4%
Growth Correlation 12m -81.9%
Growth Correlation 5y -25%
CAGR 5y -9.25%
CAGR/Mean DD 5y -0.36
Sharpe Ratio 12m -1.57
Alpha -44.46
Beta 0.60
Volatility 17.42%
Current Volume 50.6k
Average Volume 20d 20.7k
What is the price of UTMD stocks?
As of December 22, 2024, the stock is trading at USD 61.02 with a total of 50,638 shares traded.
Over the past week, the price has changed by -1.99%, over one month by -3.57%, over three months by -7.85% and over the past year by -24.39%.
Is Utah Medical Products a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Utah Medical Products (NASDAQ:UTMD) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 49.94 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of UTMD as of December 2024 is 53.66. This means that UTMD is currently overvalued and has a potential downside of -12.06%.
Is UTMD a buy, sell or hold?
Utah Medical Products has no consensus analysts rating.
What are the forecast for UTMD stock price target?
According to ValueRays Forecast Model, UTMD Utah Medical Products will be worth about 58.9 in December 2025. The stock is currently trading at 61.02. This means that the stock has a potential downside of -3.47%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 58.9 -3.5%